Crizotinib-d5
Cat. No.: IBDI-434462
Crizotinib-d5 is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.
Product Details
| Target |
Anaplastic lymphoma kinase (ALK) | c-Met/HGFR | ROS Kinase | Autophagy |
| Molecular Weight |
455.37 |
| Synonyms |
PF-02341066-d5 |
Storage & Handling
| Shipping |
Room temperature in continental US. May vary elsewhere. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.